WO2015076621A1 - 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 - Google Patents
혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 Download PDFInfo
- Publication number
- WO2015076621A1 WO2015076621A1 PCT/KR2014/011280 KR2014011280W WO2015076621A1 WO 2015076621 A1 WO2015076621 A1 WO 2015076621A1 KR 2014011280 W KR2014011280 W KR 2014011280W WO 2015076621 A1 WO2015076621 A1 WO 2015076621A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- pep
- angiogenesis
- peptide
- cells
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 92
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 81
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 66
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 239000012634 fragment Substances 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 40
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims description 38
- 150000001413 amino acids Chemical class 0.000 claims description 33
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 18
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- 230000035755 proliferation Effects 0.000 claims description 17
- 230000004614 tumor growth Effects 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 230000002792 vascular Effects 0.000 claims description 14
- 206010027476 Metastases Diseases 0.000 claims description 13
- 230000009401 metastasis Effects 0.000 claims description 13
- 208000002780 macular degeneration Diseases 0.000 claims description 11
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 10
- 201000004681 Psoriasis Diseases 0.000 claims description 9
- 208000010412 Glaucoma Diseases 0.000 claims description 8
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 8
- 208000037976 chronic inflammation Diseases 0.000 claims description 8
- 230000006020 chronic inflammation Effects 0.000 claims description 8
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 8
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 206010011017 Corneal graft rejection Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 5
- 208000022461 Glomerular disease Diseases 0.000 claims description 5
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 5
- 208000002260 Keloid Diseases 0.000 claims description 5
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 206010052428 Wound Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 230000007882 cirrhosis Effects 0.000 claims description 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 5
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 5
- 230000009545 invasion Effects 0.000 claims description 5
- 210000001117 keloid Anatomy 0.000 claims description 5
- 230000003211 malignant effect Effects 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 231100000397 ulcer Toxicity 0.000 claims description 5
- 206010000050 Abdominal adhesions Diseases 0.000 claims description 4
- 208000003732 Cat-scratch disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- 230000008595 infiltration Effects 0.000 claims description 4
- 238000001764 infiltration Methods 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 206010029333 Neurosis Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000015238 neurotic disease Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 206010002519 Animal scratch Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 43
- 230000005764 inhibitory process Effects 0.000 abstract description 15
- 108010017842 Telomerase Proteins 0.000 abstract description 10
- 108010088535 Pep-1 peptide Proteins 0.000 description 127
- 210000004027 cell Anatomy 0.000 description 95
- 206010028980 Neoplasm Diseases 0.000 description 82
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 61
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 61
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 61
- 101710113864 Heat shock protein 90 Proteins 0.000 description 52
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 52
- 235000001014 amino acid Nutrition 0.000 description 36
- 229940024606 amino acid Drugs 0.000 description 34
- 206010021143 Hypoxia Diseases 0.000 description 25
- 201000011510 cancer Diseases 0.000 description 25
- 102000004196 processed proteins & peptides Human genes 0.000 description 24
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 20
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 229910052760 oxygen Inorganic materials 0.000 description 16
- 239000001301 oxygen Substances 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 15
- 230000001146 hypoxic effect Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 230000004663 cell proliferation Effects 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 238000003119 immunoblot Methods 0.000 description 11
- 210000002889 endothelial cell Anatomy 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000007954 hypoxia Effects 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- LZGGUFLRKIMBDQ-BJMVGYQFSA-N (3e)-3-(1,3-benzodioxol-5-ylmethylidene)-2-oxopyrrolidine-1-carbaldehyde Chemical compound O=C1N(C=O)CC\C1=C/C1=CC=C(OCO2)C2=C1 LZGGUFLRKIMBDQ-BJMVGYQFSA-N 0.000 description 8
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- 108050006400 Cyclin Proteins 0.000 description 7
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 7
- 229950007866 tanespimycin Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 101100285899 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SSE2 gene Proteins 0.000 description 6
- 230000002491 angiogenic effect Effects 0.000 description 6
- -1 aromatic amino acids Chemical class 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 239000000411 inducer Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 108091035539 telomere Proteins 0.000 description 5
- 210000003411 telomere Anatomy 0.000 description 5
- 102000055501 telomere Human genes 0.000 description 5
- 210000003606 umbilical vein Anatomy 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 4
- 102100022338 Integrin alpha-M Human genes 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 238000010562 histological examination Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000010212 intracellular staining Methods 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 2
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 230000035519 G0 Phase Effects 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 101150112743 HSPA5 gene Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 description 2
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 101150028578 grp78 gene Proteins 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000007959 normoxia Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 239000003207 proteasome inhibitor Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 231100000747 viability assay Toxicity 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 1
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 1
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 1
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 1
- KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 1
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 1
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- VCFCFPNRQDANPN-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCC)C(O)=O)C3=CC=CC=C3C2=C1 VCFCFPNRQDANPN-IBGZPJMESA-N 0.000 description 1
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 1
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 1
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- NALREUIWICQLPS-UHFFFAOYSA-N 7-imino-n,n-dimethylphenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[N+](C)C)C=CC3=NC2=C1 NALREUIWICQLPS-UHFFFAOYSA-N 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- BHSYMWWMVRPCPA-CYDGBPFRSA-N Arg-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N BHSYMWWMVRPCPA-CYDGBPFRSA-N 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- MECFLTFREHAZLH-ACZMJKKPSA-N Asn-Glu-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N MECFLTFREHAZLH-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQWMZOIPXWSZNE-WDSKDSINSA-N Gln-Asp-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O WQWMZOIPXWSZNE-WDSKDSINSA-N 0.000 description 1
- YYOBUPFZLKQUAX-FXQIFTODSA-N Glu-Asn-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O YYOBUPFZLKQUAX-FXQIFTODSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100032510 Heat shock protein HSP 90-beta Human genes 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001016856 Homo sapiens Heat shock protein HSP 90-beta Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 102000002177 Hypoxia-inducible factor-1 alpha Human genes 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- IPFKIGNDTUOFAF-CYDGBPFRSA-N Ile-Val-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IPFKIGNDTUOFAF-CYDGBPFRSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- 101000988090 Leishmania donovani Heat shock protein 83 Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- WEMYTDDMDBLPMI-DKIMLUQUSA-N Phe-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N WEMYTDDMDBLPMI-DKIMLUQUSA-N 0.000 description 1
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101001045444 Proteus vulgaris Endoribonuclease HigB Proteins 0.000 description 1
- 101001100822 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Pyocin-S2 Proteins 0.000 description 1
- 101001100831 Pseudomonas aeruginosa Pyocin-S1 Proteins 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- KHPLUFDSWGDRHD-SLFFLAALSA-N Tyr-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O KHPLUFDSWGDRHD-SLFFLAALSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 230000009762 endothelial cell differentiation Effects 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007111 proteostasis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 108010004034 stable plasma protein solution Proteins 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a peptide having an angiogenic inhibitory effect and a pharmaceutical composition comprising the same. More specifically, the present invention relates to a peptide derived from telomerase, a peptide having an angiogenic inhibitory effect, and a pharmaceutical composition for inhibiting angiogenesis.
- the proliferation, differentiation and disappearance of cells and tissues for maintaining body homeostasis are regulated by the balance of interactions between cells and various cell stimulating factors present in the extracellular matrix.
- various diseases such as no response to apoptosis or proliferation inhibitory signal, nutrient supply by continuous angiogenesis, malignant tumors represented by infiltration and metastasis to surrounding tissues occur.
- Angiogenesis includes the entire process of cell basement membrane degradation, cell migration and extracellular matrix invasion, cell proliferation, capillary lumen formation and perivascular cell formation.
- Inhibition methods include direct methods of targeting vascular endothelial cells and indirect methods of targeting cancer cells or peripheral cells generating angiogenesis inducers.
- the research has been focused mainly on the development of antibody proteins that inhibit the activity of angiogenesis inducers or the development of low molecular materials that block the action of their receptors.
- Angiogenesis occurs through a series of sequential steps, including the migration and division of endothelial cells that form the vessel wall. About 15 kinds of proteins that activate the growth and migration of endothelial cells are known, and such angiogenesis may be regulated by such factors. Therefore, the formation of neovascularization may include angiogenin, epidermal growth factor, estrogen, fibroblast growth factor, inerleukin 8, prostaglandin E1 and E2, tumor necrosis factor, vascular endothelial growth factor, or G-CSF (granulocyte). and inhibitors that inhibit activating proteins such as colony-stimulating factors).
- HSP Heat Shock Protein
- HSP90 and HSP70 have been described in a wide range of tumors [Morano KA, Annals of the New York Academy of Sciences, 1113: 1-14, 2007; Calderwood SK et al, Trends in biochemical sciences, 31: 164-72, 2006].
- the expression of some HSPs has been shown to correlate with the proliferation, differentiation and apoptosis of tumor cells in some cancers, indicating that HSPs play an important role in cancer cell survival because of their cellular protective role.
- HSP70 Overexpression of HSP70 leads to tumorigenesis of rat fibrosarcoma cells, and overexpression of HSP70 in transgenic mouse T-cells leads to an increase in T-cell lymphoma in rats [Jaattela M, International journal of cancer Journal international du cancer, 60: 689-93, 1995; Seo JS et al, Biochemical and biophysical research communications, 218: 582-7, 1996; Volloch VZ et al, Oncogene, 18: 3648-51, 1999; Murphy ME, Carcinogenesis, 34: 1181-8, 2013].
- HSP70 is known to play an important role in protecting cells from apoptosis.
- anti-angiogenic drugs based on the theory that blocking the production of blood vessels that supply oxygen and nutrients to cells inhibits the growth and metastasis of cancer and finally can cure cancer, not only anticancer drugs, but also arthritis, diabetes It is actively researched as a target therapy that can be applied to retinopathy, chronic inflammation, and ischemic heart disease.
- angiogenesis therapy can indirectly normalize the tumor vascular environment, improving the effective delivery of biologics or chemotherapeutic agents and improving the hypoxic environment. Can be promoted.
- various diseases such as malignant tumors (arthritis, diabetic retinopathy and chronic inflammation, ischemic heart disease, etc.), excessive angiogenesis-related tumors (cancer), cardiovascular diseases (e.g. atherosclerosis), chronic inflammation (e.g.
- cancer e.g. atherosclerosis
- cardiovascular diseases e.g. atherosclerosis
- chronic inflammation e.g.
- anti-angiogenic drugs to treat or prevent rheumatoid arthritis or Crohn's disease
- diabetes eg, diabetic retinopathy
- psoriasis endometriosis.
- An object according to an aspect of the present invention is to provide a peptide having an effective angiogenesis inhibitory activity, a composition for inhibiting angiogenesis comprising the same and a method for treating angiogenesis-related diseases using the same.
- An object according to another aspect of the present invention is to provide a composition capable of effectively preventing and treating angiogenesis-related diseases.
- a composition comprising a peptide comprising an amino acid sequence of SEQ ID NO: 1, a peptide having a sequence homology of 80% or more with the amino acid sequence, or a fragment thereof is a peptide for inhibiting angiogenesis.
- the fragment may be a fragment consisting of three or more amino acids.
- the composition may be characterized by inhibiting the proliferation or tube formation of vascular endothelial cells.
- the composition may be characterized by inhibiting the proliferation of vascular endothelial cells, vascularization or invasion of vascular endothelial cells by Vascular endothelial growth factor-A (VEGF-A) have.
- VEGF-A Vascular endothelial growth factor-A
- the composition may be for the prevention and treatment of diseases associated with angiogenesis.
- the fragment may be a fragment consisting of three or more amino acids.
- the composition is tumor growth and metastasis, diabetic retinopathy, prematurity retinopathy, corneal graft rejection, neovascular glaucoma, erythematosis, proliferative retinopathy, psoriasis, macular degeneration (macular degeneration), hemophiliac joints, capillary hyperplasia in atherosclerotic plaques, keloids, wound granulation, vascular adhesion, rheumatoid arthritis, chronic inflammation, osteoarthritis, autoimmune diseases, Crohn's disease, restenosis, Atherosclerosis, intestinal adhesion, cat scratch disease, ulcers, cirrhosis, glomerulonephritis, diabetic nephropathy, malignant neurosis, thrombotic microangiopathy, organ transplant rejection, renal glomerulopathy, diabetes, inflammatory or neurodegenerative diseases It may be used for the prevention or treatment of regulatory
- the composition for inhibiting angiogenesis may be used for the prevention or treatment of tumor growth and metastasis.
- the composition for inhibiting angiogenesis may be used for the prevention or treatment of eye diseases due to excessive angiogenesis.
- the ophthalmic disease is diabetic retinopathy, prematurity retinopathy, corneal transplant rejection, neovascular glaucoma, erythematosis, proliferative retinopathy, psoriasis or macular degeneration Can be.
- the composition may be to inhibit the proliferation of vascular endothelial cells, Vascular endothelial growth factor (VEGF) -induced vascular formation and infiltration of vascular endothelial cells.
- VEGF Vascular endothelial growth factor
- the composition may be a pharmaceutical composition.
- the composition may be a food composition.
- it may be a method for preventing and treating angiogenesis-related diseases comprising administering to the subject the above-mentioned composition.
- the disease associated with angiogenesis is tumor growth and metastasis, diabetic retinopathy, prematurity retinopathy, corneal graft rejection, neovascular glaucoma, erythematosis, proliferative retinopathy, psoriasis, macular degeneration (macular degeneration), hemophiliac joints, capillary hyperplasia in atherosclerotic plaques, keloids, wound granulation, vascular adhesion, rheumatoid arthritis, chronic inflammation, osteoarthritis, autoimmune diseases, Crohn's disease, restenosis, Atherosclerosis, intestinal adhesion, cat scratch disease, ulcers, cirrhosis, glomerulonephritis, diabetic nephropathy, malignant neurosis, thrombotic microangiopathy, organ transplant rejection, renal glomerulopathy, diabetes, inflammatory or neurodegenerative diseases It may be adjustable.
- a method for treating and preventing angiogenesis-related diseases characterized in that for administering to the subject in need of the composition for inhibiting angiogenesis.
- the composition according to the present invention can be provided a composition capable of effectively inhibiting angiogenesis. Therefore, the composition according to the present invention can be applied to the treatment and prevention of diseases related to angiogenesis, and in particular can be used for the treatment of eye diseases due to tumor growth and metastasis inhibition, excessive angiogenesis.
- a peptide having a sequence of SEQ ID NO: or a peptide or fragment having a sequence having 80% homology with the sequence according to the present invention has excellent angiogenesis inhibitory effect.
- FIGS. 1 and 2 are photographs showing the results of PEP 1 inhibiting HIF-1 ⁇ production in hypoxia induced cells.
- MCF7 and HeLa cells were treated with PEP 1 (20 ⁇ M) or vehicle and incubated at low oxygen for a specified time. Cell lysates were subjected to immunoblotting to analyze the amount of HIF-1 ⁇ .
- FIG. 3 is a graph showing hypoxia induced VEGF production inhibition by PEP 1.
- MCF7 and HeLa cells were treated with PEP 1 (20 ⁇ M) or vehicle and incubated in normal and low oxygen conditions for the designated time.
- the amount of secreted VEGF in the cell culture supernatant was confirmed by ELISA (versus mock * is p ⁇ 0.05, ** is p ⁇ 0.01, ⁇ represents p ⁇ 0.001, respectively).
- FIG. 4 and 5 are the results showing the down-regulatio of HSP70 and HSP90 according to PEP 1 treatment in cancer cells.
- Jurkat FIG. 4
- MCF7 FIG. 5
- the amount of protein of HSP70 and HSP90 was analyzed by immunoblotting using antibodies against HSP70, HSP90 and GAPDH.
- 6 and 7 are experimental results showing hypoxia induced HSP production inhibition by PEP 1.
- MCF7 and HeLa cells were treated with PEP 1 (20 ⁇ M) or vehicle and incubated at low oxygen for a designated time. Cell lysates were subjected to immunoblotting to analyze the amounts of HSP70 and HSP90.
- Figure 8 shows the results of treatment of vehicle, PEP 1, 17-AAG, KNK437 to Jurkat and MCF7 cells.
- Jurkat and MCF7 cells were treated with vehicle, PEP 1 (5 ⁇ M for Jurkat and 20 ⁇ M for MCF7), 17-AAG (1 ⁇ M), KNK437 (1 ⁇ M) in serum-free medium for 2 hours.
- Cell lysates were analyzed by immunoblotting in a similar manner used in FIG. 4.
- FIG. 9 shows the results of treatment of MCF7 cells with PEP 1 or PBS in both without and including MG132 (5 ⁇ M).
- Intracellular HSPs and cell surface HSPs were stained by surface intracellular staining and surface staining staining and analyzed using flow cytometry, as described in the test materials and methods (red: DMSO; blue: PEP 1 + DMSO; orange: PEP 1 + MG132; green: MG132).
- FIGS. 12 and 13 show the effect of PEP 1 on Tie2 + monocyte aggregation in tumor cells.
- Tie2 + CD11b + monocyte aggregates were analyzed using immunofluorescence staining for detection of Tie2 (Green, AlexaFlour 488) and CD11b (Red, AelxaFlour633). Cell nuclei were visualized using DAPI staining. Scale bars represent 50 ⁇ m. Arrows in the enlarged image indicate Tie2 + CD11b + . Macrophages are expressed per hpf. Five fields were randomly selected from two slides of each tumor tissue treatment group for quantification (* denotes p ⁇ 0.05, ** denotes p ⁇ 0.01, *** denotes p ⁇ 0.001, 2-way t) use -test).
- HSP70 and HSP90 protein levels of tumors by PEP 1 treatment show the reduction of HSP70 and HSP90 protein levels of tumors by PEP 1 treatment.
- HSP70 and HSP90 protein levels in tumor sections were visualized by immunohistochemical staining with antibodies against HSP70 and HSP90 (FIG. 14) and quantified using Leica Qwin software (FIG. 15). Randomly selected to quantify 10 fields from 6 slides in each treatment group (data is expressed as mean ⁇ SD, * indicates p ⁇ 0.05 when compared to control, using 2-way T-test) ). Protein extracts from tumors were subjected to immunoblotting using antibodies against HSP70, HSP90, GRP78, and GAPDH (FIG. 16).
- FIG. 17 and 18 are results showing the effect on the HSP70 level secreted in the blood of PEP 1.
- 25A and 25B are experiments for evaluating angiogenesis inhibitory effect of PEP 1, and treatment of PEP 1 with concentrations (0.05, 0.5, 5 ⁇ M) in vascular endothelial cells (Human umbilical vein endothelial cells), followed by cell proliferation Figure 1a) and cell survival rate (Fig. 1b) by measuring the results of vascular endothelial cell proliferation inhibitory effect is shown.
- 26A and 26B are experiments for evaluating angiogenesis inhibitory effect of PEP 1 and after observing PEP 1 by concentration (0.05, 0.5, 5 ⁇ M) in vascular endothelial cells (FIG. 2A) and graphing it Figure 2b shows the effect of inhibiting vascular endothelial tube formation.
- 27A and 27B are tests for evaluating the angiogenesis inhibitory effect of PEP 1 and the concentration of PEP 1 in vascular endothelial cells induced by VEGF-A (VGF) -induced angiogenesis inducer (0.05, 0.5, 5 ⁇ M), cell proliferation (FIG. 3A) and cell viability (FIG. 3B) were measured to show the effect of inhibiting vascular endothelial cell proliferation.
- VGF VEGF-A
- FIG. 3B cell viability
- Figures 28a and 28b is a test for evaluating the angiogenesis inhibitory effect of PEP 1 to the endothelial cells induced by vascular endothelial growth factor-A (VEGF-A) -induced angiogenesis induced PEP 1 by concentration (0.05, 0.5, 5 ⁇ M), and then observed (Fig. 4a) and graphed it (Fig. 4b) shows the effect of inhibiting vascular endothelial tube formation.
- VEGF-A vascular endothelial growth factor-A
- Fig. 29 is a schematic diagram showing the installation of a transwell insert.
- 30A and 30B are tests for evaluating the angiogenesis inhibitory effect of PEP 1 and the concentration of PEP 1 in vascular endothelial cells induced by Vascular Endothelial Growth Factor-A (VEGF-A) induced by angiogenesis inducer (0.05, 0.5, 5 ⁇ M), the insert was fixed with methanol and the non-infiltrated cells of the insert were removed (FIG. 6A) and graphed (FIG. 6B) to observe the effect of inhibiting vascular endothelial cell infiltration. .
- VEGF-A Vascular Endothelial Growth Factor-A
- the present invention may be variously modified and may have various embodiments.
- the present invention will be described in more detail. However, this is not intended to limit the present invention to specific embodiments, it should be understood to include all transformations, equivalents, and substitutes included in the spirit and scope of the present invention.
- the detailed description of the related known technology may obscure the gist of the present invention, the detailed description thereof will be omitted.
- Telomere is a genetic material repeatedly present at the end of a chromosome and is known to prevent damage to the chromosome or binding to another chromosome. Each time a cell divides, the telomeres become slightly shorter. After a certain number of cell divisions, the telomeres become very short, and the cells stop dividing and die. On the other hand, elongation of telomeres is known to prolong cell life. For example, cancer cells secrete an enzyme called telomerase, which prevents telomeres from shortening, so that cancer cells can continue to proliferate without dying. The inventors have confirmed that peptides derived from telomerase are effective in inhibiting angiogenesis and have completed the present invention.
- neovascular growth is associated with diseases such as cancer, age-related macular degeneration, rheumatoid arthritis, and psoriasis.
- diseases such as cancer, age-related macular degeneration, rheumatoid arthritis, and psoriasis.
- excessive blood vessel growth results in the supply of new blood vessels to the diseased tissue, destroying normal tissues.
- new blood vessels may circulate tumor cells and parasitic other tissues.
- Such angiogenesis-related diseases include diabetic retinopathy, prematurity retinopathy, corneal graft rejection, neovascular glaucoma, melanoma, proliferative retinopathy, psoriasis, macular degeneration, hemophilia sexual joint, capillary hyperplasia in atherosclerotic plaques, keloids, wound granulation, vascular adhesion, rheumatoid arthritis, chronic inflammation, osteoarthritis, autoimmune diseases, Crohn's disease, restenosis, atherosclerosis, intestinal adhesion , Cat scratch disease, ulcers, cirrhosis, glomerulonephritis, diabetic nephropathy, malignant neuropathy, thrombotic microangiopathy, organ transplant rejection, renal glomerulopathy, unregulated angiogenesis-related disorders of diabetes, inflammatory or neurodegenerative diseases
- diseases or disorders include, but are not limited to.
- retinopathy As such, it is useful as a therapeutic agent for diabetic retinopathy, prematurity retinopathy, macular degeneration, neovascular glaucoma, retinal vein occlusion, retinal artery occlusion, pterygium, rubeosis, corneal neovascularism, solid tumor, hemangioma, tumor growth and metastasis.
- Searching for compounds with angiogenesis inhibitory activity can be said to search for drugs applicable to the treatment of a wide range of diseases.
- HSP90 is closely related to tumorigenesis by regulating important client proteins in cell survival and tumor growth [Calderwood SK, Trends in biochemical sciences. 31, 164-72, 2006; Garcia-Carbonero R et al, The lancet oncology, 14, e358-69, 2013].
- the list of such client proteins includes chirosine kinase receptors, signaling proteins, cell cycle proteins, anti-cell killer proteins, etc. [Garcia-Carbonero R et al., The lancet oncology. 14, e358-69, 2013].
- HIF-1 ⁇ (alpha) plays a central role in inducing angiogenesis under hypoxic conditions.
- HSP90 leads to increased tumor angiogenesis [Sun J et al, Arteriosclerosis, thrombosis, and vascular biology., 24: 2238-44, 2004; Pfosser A et al, Cardiovascular research. 65: 728-36. 2005]. Both HSP70 and HSP90 are found locally in extracellular gaps and plasma membranes [Ferrarini M et al, International journal of cancer Journal international du cancer. 51: 613-9. 1992; Vanbuskirk A et al, The Journal of experimental medicine.
- HSP70 released from tumors is very closely related to some types of tumor progression and poor prognosis [Yeh CH et al, Leukemia research, 34: 605-9, 2010; Kocsis J et al, Cell stress & chaperones, 15: 143-51, 2010], HSP70 serum levels were found to be associated with internal levels of HSP70 [Dempsey NC et al, Journal of leukocyte biology, 87: 467-76 , 2010].
- HSP90 has also been a target of pharmaceutical treatment and several candidates have been developed [Evans CG et al, Journal of medicinal chemistry, 53: 4585-602, 2010; Powers MV et al, Cell cycle, 9: 1542-50, 2010].
- the present invention finds the effect of PEP 1 on HIF-1 ⁇ and VEGF levels under cancer cell growth and normal oxygen and hypoxic conditions, and evaluates the in vivo efficacy of PEP 1 using a xenograft mouse model. The experiment was performed.
- the treatment of PEP 1 to cancer cells reduced the production of HIF1- ⁇ and VEGF in the hypoxic state, and the treatment of PEP 1 to cancer cells was confirmed to lower the levels of HSP70 and HSP90 protein.
- a peptide of SEQ ID NO: 1, a peptide that is a fragment of SEQ ID NO: 1, or a peptide having a sequence homology of at least 80% with the peptide sequence is used in telomerase, specifically in human ( Homo sapiens ) telomerase. Peptides derived.
- Peptides disclosed herein can include peptides having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% homology.
- the peptides disclosed herein, peptides or fragments thereof comprising SEQ ID NO: 1 and one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, five or more amino acids, six or more amino acids Or peptides with seven or more amino acids changed.
- amino acid changes belong to a property that allows the physicochemical properties of the peptide to be altered.
- amino acid changes can be made, such as improving the thermal stability of the peptide, altering substrate specificity, changing the optimal pH, and the like.
- amino acid includes not only the 22 standard amino acids that are naturally incorporated into the peptide, but also D-isomers and modified amino acids. Accordingly, in one aspect of the invention the peptide may be a peptide comprising D-amino acids. Meanwhile, in another aspect of the present invention, the peptide may include a non-standard amino acid or the like which has been post-translational modified.
- post-translational modifications include phosphorylation, glycosylation, acylation (including, for example, acetylation, myristoylation and palmitoylation), alkylation ), Carboxylation, hydroxylation, glycation, biotinylation, ubiquitinylation, changes in chemical properties (e.g., beta-elimination deimidization) , Deamidation) and structural changes (eg, formation of disulfide bridges). It also includes changes in amino acids, such as changes in amino groups, carboxy groups or side chains, caused by chemical reactions that occur during the linkage with crosslinkers to form peptide conjugates.
- Peptides disclosed herein can be wild-type peptides identified and isolated from a natural source.
- the peptides disclosed herein may be artificial variants, comprising an amino acid sequence in which one or more amino acids are substituted, deleted and / or inserted compared to peptides that are fragments of SEQ ID NO: 1.
- Amino acid changes in the wild type polypeptide as well as in artificial variants include conservative amino acid substitutions that do not significantly affect the folding and / or activity of the protein.
- conservative substitutions include basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine, valine and methionine), aromatic amino acids (phenylalanine, Tryptophan and tyrosine), and small amino acids (glycine, alanine, serine and threonine). Amino acid substitutions that generally do not alter specific activity are known in the art.
- the most common exchanges are Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Tyr / Phe, Ala / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, and Asp / Gly, and vice versa.
- Other examples of conservative substitutions are shown in the following table.
- Substantial modifications in the biological properties of the peptide include (a) their effect on maintaining the structure of the polypeptide backbone, eg, a sheet or helical conformation, within the substitution region, (b) the charge of the molecule at the target site. Or their effect in maintaining hydrophobicity, or (c) their effect in maintaining the bulk of the side chains, is carried out by selecting significantly different substitutions. Natural residues are divided into the following groups based on common side chain properties:
- hydrophobic norleucine, met, ala, val, leu, ile
- Non-conservative substitutions will be made by exchanging a member of one of these classes for another class. Any cysteine residue that is not involved in maintaining the proper conformation of the peptide can generally be substituted with serine to improve the oxidative stability of the molecule and to prevent abnormal crosslinking. Conversely, cysteine bond (s) can be added to the peptide to improve its stability.
- Another type of amino acid variant of the peptide is a change in the glycosylation pattern of the antibody.
- change is meant the deletion of one or more carbohydrate residues found in the peptide and / or the addition of one or more glycosylation sites that are not present in the peptide.
- N-linked refers to a carbohydrate moiety attached to the side chain of an asparagine moiety.
- Tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are recognition sequences for enzymatic attachment of carbohydrate moieties to asparagine side chains.
- O-linked glycosylation means attaching one of the sugars N-acetylgalactosamine, galactose or xylose to hydroxyamino acids, most commonly serine or threonine, but 5-hydroxyproline or 5-hydroxylysine You can also use
- glycosylation sites to the peptide is conveniently performed by changing the amino acid sequence to contain one or more of the above mentioned tripeptide sequences (for N-linked glycosylation sites). Such changes may also be made by adding or replacing one or more serine or threonine residues with the sequence of the original antibody (for O-linked glycosylation sites).
- a peptide having a sequence of SEQ ID NO: 1, a peptide which is a fragment of SEQ ID NO: 1, or a peptide having a sequence homology of 80% or more with the peptide sequence according to an aspect of the present invention has low intracellular toxicity and stability in vivo. This has the advantage of being high.
- SEQ ID NO: 1 in the present invention is a telomerase-derived peptide consisting of 16 amino acids as follows.
- the peptide described in SEQ ID NO: 1 is shown in Table 1 below. "Name” in Table 2 below is named to distinguish peptides.
- the peptide set forth in SEQ ID NO: 1 represents the entire peptide of human telomerase.
- a peptide having a sequence of SEQ ID NO: 1, a peptide that is a fragment of SEQ ID NO: 1, or a peptide having at least 80% sequence homology with the peptide sequence corresponds to a peptide included in telomerase.
- synthetic peptides selected and synthesized at the positional peptides.
- SEQ ID 2 shows the amino acid sequence of the entire telomerase.
- a peptide comprising the amino acid sequence of SEQ ID NO: 1 (comprising), a peptide having a sequence homology of 80% or more with the amino acid sequence or a fragment thereof as an active ingredient comprising a peptide having an angiogenesis inhibitory effect It provides a pharmaceutical composition.
- composition for inhibiting angiogenesis comprises a peptide comprising an amino acid sequence of SEQ ID NO: 1 in one aspect, a peptide having a sequence homology of 80% or more with the amino acid sequence, or a peptide thereof.
- g / L to 1kg / L specifically 0.1g / L to 100g / L, more specifically, may be included in the content of 1g / L to 10g / L, but can be appropriately adjusted if the difference in effect according to the dose is shown.
- composition according to one aspect of the present invention can be applied to all animals including humans, dogs, chickens, pigs, cattle, sheep, guinea pigs or monkeys.
- the composition is a pharmaceutical comprising a peptide comprising an amino acid sequence of SEQ ID NO: 1 (comprising), a peptide having an angiogenesis inhibitory activity, a peptide having a sequence homology of 80% or more with the amino acid sequence or a fragment thereof To provide a composition.
- the pharmaceutical composition according to one aspect of the present invention may be administered orally, rectal, transdermal, intravenous, intramuscular, intraperitoneal, intramedullary, intradural or subcutaneous.
- Formulations for oral administration may be, but are not limited to, tablets, pills, soft or hard capsules, granules, powders, solutions or emulsions.
- Formulations for parenteral administration may be, but are not limited to, injections, drops, lotions, ointments, gels, creams, suspensions, emulsions, suppositories, patches or sprays.
- compositions according to one aspect of the invention may include additives such as diluents, excipients, lubricants, binders, disintegrants, buffers, dispersants, surfactants, colorants, flavoring or sweetening agents as needed.
- additives such as diluents, excipients, lubricants, binders, disintegrants, buffers, dispersants, surfactants, colorants, flavoring or sweetening agents as needed.
- Pharmaceutical compositions according to one aspect of the invention may be prepared by conventional methods in the art.
- the active ingredient of the pharmaceutical composition according to one aspect of the present invention will vary depending on the age, sex, weight, pathology and severity of the subject to be administered, the route of administration or the judgment of the prescriber. Dosage determination based on these factors is within the level of one of skill in the art and its daily dosage may be, for example, 10 ng / kg / day to 10 mg / kg / day, specifically 0.1 ⁇ g / kg / day to 1 mg / kg / day, More specifically, it may be 1 ⁇ g / kg / day to 100 ⁇ g / kg / day, and more specifically, 2 ⁇ g / kg / day to 50 ⁇ g / kg / day, but the difference in effect depending on the dose This can be adjusted appropriately.
- the pharmaceutical composition according to one aspect of the present invention may be administered once to three times a day, but is not limited thereto.
- the composition is for inhibiting angiogenesis comprising as an active ingredient a peptide comprising an amino acid sequence of SEQ ID NO: 1, a peptide having a sequence homology of 80% or more with the amino acid sequence or a fragment thereof.
- a food composition comprising as an active ingredient a peptide comprising an amino acid sequence of SEQ ID NO: 1, a peptide having a sequence homology of 80% or more with the amino acid sequence or a fragment thereof.
- the formulation of the food composition according to one aspect of the present invention is not particularly limited, but may be, for example, formulated into tablets, granules, powders, solutions, solid preparations, and the like.
- Each formulation may be appropriately selected and formulated by those skilled in the art according to the formulation or purpose of use, in addition to the active ingredient, and may be synergistic when applied simultaneously with other raw materials.
- Preferred embodiments of the invention include the most optimal mode known to the inventors for carrying out the invention. Variations of the preferred embodiments may become apparent to those skilled in the art upon reading the foregoing description. The inventors expect those skilled in the art to make appropriate use of such variations, and the inventors expect the invention to be practiced in a manner different from that described herein. Accordingly, the invention includes all modifications and equivalents of the subject matter referred to in the appended claims, as permitted by patent law. Moreover, any combination of the abovementioned elements within all possible variations is included in the invention unless expressly stated to the contrary or apparently contradictory in context. While the invention has been particularly shown and described with reference to exemplary embodiments, those skilled in the art will understand that various changes in form and detail may be made without departing from the spirit and scope of the invention as defined by the following claims .
- human umbilical vein endothelial cells were used to determine the direct inhibitory effect on the proliferation, angiogenesis and cell invasion of vascular endothelial cells of peptide PEP 1.
- PEP 1 The peptide of SEQ ID NO: 1 (hereinafter referred to as "PEP 1") was prepared according to the solid phase peptide synthesis known in the art. Specifically, peptides were synthesized by coupling amino acids one by one from the C-terminus through Fmoc solid phase synthesis (SPPS) using ASP48S (Peptron, Inc., Daejeon, Korea). As follows, the first amino acid at the C-terminus of the peptides was attached to the resin. For example:
- Coupling reagent is HBTU [2- (1H-Benzotriazole-1-yl) -1,1,3,3-tetamethylaminium hexafluorophosphate] / HOBt [N-Hydroxxybenzotriazole] / NMM [4-Methylmorpholine] It was. Fmoc removal was performed using piperidine in DMF in 20% of DMF.
- Each peptide was synthesized by repeating a process of reacting the amino acids with each other, washing with a solvent, and then deprotecting the amino acid using the state in which the amino acid protecting group was bound to the solid support.
- the synthesized peptide was separated from the resin and then purified by HPLC, and confirmed by MS and lyophilized.
- Human breast cancer cell lines MCF7 Human breast adenocarcinoma cell line
- human T lymphocyte cell line human T lymphocyte cell line (Jurkat)
- MC38 murine colon adenocarcinoma
- Fetal bovine Serum 10% Fetal bovine Serum and 100 U / ml penicillin and streptomycin Streptomycin was maintained in the added RPMI1460 medium.
- HeLa human cervical adenocarcinoma cell lines were maintained in DMEM (Dulbecco's modified Eagle's medium) medium supplemented with 10% fetal bovine serum (Fetal Bovine Serum) and 100 U / ml penicillin and streptomycin.
- MCF7 and HeLa cells were incubated in the low and normal oxygen state after treatment with 20 ⁇ M PEP 1.
- Anoxia was induced using BBL GasPak (Becton Dickinson), which catalyzes within 90 minutes and reduces oxygen to undetectable levels. Incubation time ranged from 2 to 24 hours.
- Cells were harvested and immunoblotted using ⁇ -HSP70, ⁇ -HSP90, ⁇ -HIF-1 ⁇ , or ⁇ -GAPDH antibodies as described above.
- ⁇ -GAPDH is used to normalize the amount of HSP70 / 90 to the amount of GAPDH for protein quantification.
- MCF7 and HeLa cells were inoculated into 96 well plates at 1 ⁇ 10 4 cells per well, followed by 37 ° C. in a complete medium containing 10% FBS. Incubated at 5% CO 2 . After serum starvation for 2 hours, they were cultured in all complete media, including PEP 1 (20 ⁇ M). Cells were cultured in low or normal oxygen conditions for one to six days as described above. The number of viable cells was measured daily using tryphan blue exclusion method. All calculation experiments were performed in duplicate.
- Jurkat and MCF7 cells (5 ⁇ 10 5 ) were inoculated for 12 hours and incubated. After 2 hours starvation with OPTI-MEM medium, cells were treated with different concentrations of PEP 1, scrambled peptide and 17-AAG (1 ⁇ M) or KNK437 (1) as shown in the figure. ⁇ M). After incubation for 2 hours, cells were harvested and lysed using cell lysis buffer (Thermo Scientific, IL, USA).
- MCF7 cells were treated with PEP 1 or control.
- PEP 1 phosphate buffered saline
- FACS buffer PBS containing 1% BSA and 0.1% NaN 3
- Cells were treated with permeabilization buffer (eBioscience, CA, USA) according to the manufacturer's instructions for intracellular staining.
- Cells were reacted with ⁇ -HSP70-FITC (ab61907, Abcam) or ⁇ -HSP90-PE (ab65171, Abcam) at 4 ° C. for 30 minutes.
- Flow cytometry was performed using a FACScan flow cytometer (Becton Dickinson Co., CA, USA). Data was analyzed using Flowjo TM software (version 10.0.5, Tree Star, Inc., OR, USA).
- PEP 1 50 ⁇ g / kg in 100 ⁇ l 0.9% NaCl solution
- PBS intraperitoneally once every two days.
- volume (mm 3 ) ((width 2 x length) / 2).
- mice were sacrificed and tumor weights were measured. All animal experiments were approved by The Institute for Experimental Animals, College of Medicine, Seoul National University at Seoul, Korea.
- HSP70 and HSP90 proteins were used as primary antibodies. Expression of HSP70 and HSP90 proteins by tumors was assessed by immunoblotting using tumor lysate.
- the tumors were mortared and extracted with extraction buffer, 20 mM HEPES, pH7.5, 100 mM NaCl, 0.05% Triton X-100, 1 mM DTT, 0.5 mM sodium orthovanadate, 1 mM EDTA, 0.5 mM PMSF, 10 ⁇ g / ml aprotinin, 5 ⁇ g / ml leupeptin, 2 ⁇ g / ml pepstatin). After repeated centrifugation, the supernatants were subjected to SDS-PAGE and immunoblotting as described above.
- extraction buffer 20 mM HEPES, pH7.5, 100 mM NaCl, 0.05% Triton X-100, 1 mM DTT, 0.5 mM sodium orthovanadate, 1 mM EDTA, 0.5 mM PMSF, 10 ⁇ g / ml aprotinin, 5 ⁇ g / ml leupeptin, 2 ⁇ g
- VEGF secretion of cancer cells was confirmed by ELISA (Enzyme-linked immunosorbent assay). MCF7 and HeLa cells were cultured in low or normal oxygen state after addition of PEP 1 or vehicle for 24 hours. The amount of VEGF in the cell supernatant was determined using the human VEGF immunoassay kit (R & D Systems, USA) according to the manufacturer's instructions. To analyze the concentrations of HSP70 and HSP90 in the blood, blood was taken from a mouse model with tumors. After serum preparation, the concentrations of HSP70 and HSP90 in the blood were confirmed using an immunoassay kit for HSP70 (R & D systems, USA) and HSP90 (Cusabio Biotech co., Ltd, DE, USA.).
- the sliced tumor sections were fixed for 15 minutes at room temperature with 4% paraformaldehyde. After washing twice with PBS, incubated in PBS containing 0.25% Triton X-100 for 10 minutes, and then washed three times again with PBS. Tissue was blocked for 30 min with 1% BSA-PBST and then in a humid chamber at 4 ° C with a mixture of mouse anti-Tie2 (557039, BD Pharmigen) and rat anti-CD11b antibodies (ab8878, abcam). Incubated. After washing, the tissues were incubated with a mixture of AlexaFlour 488 goat anti-mouse IgG and AelxaFlour633 goat anti-rat IgG. In order to visualize the cell nuclei, the cells were incubated with DAPI (Sigma Aldrich) for 1 minute and analyzed by confocal microscopy.
- DAPI Sigma Aldrich
- Hypoxia Inducible Factor-1 alpha is a substance that is activated in response to hypoxic stimulation and various growth factors and cytokines and is known to play an important role in the formation of neovascularization in ischemic tissues.
- VEGF Vacular Endothelial Growth Factor
- HIF-1 ⁇ Hypoxia Inducible Factor-1 alpha
- the present invention investigates the effect of PEP 1 on the protein level of HIF-1 ⁇ under hypoxic conditions, and HIF-1 ⁇ regulates the production of VEGF (Vasecular Endothelial Growth Factor) under hypoxic conditions. It has been known that the treatment of PEP 1 affects the synthesis of VEGF induced by hypoxic conditions.
- VEGF Vasecular Endothelial Growth Factor
- HIF-1 ⁇ decreased over time in hypoxic conditions in MCF7 and HeLa cells (see FIGS. 1 and 2). That is, in the mock treated control, the expression of HIF-1 ⁇ was increased by hypoxia, but it was confirmed that the cells treated with PEP 1 were greatly reduced.
- HIF-1 ⁇ which affects angiogenesis
- PEP 1 could affect the protein levels of HSP70 and HSP90.
- treatment with PEP 1 for 2 hours reduced to significant levels of both HSP70 and HSP90 in Jurkat T-cell lymphoma cells and MCF7 breast cancer cells.
- 5 ⁇ M of PEP 1 reduced HSP70 and HSP90 by more than 50%.
- HSP90 was reduced by up to 20% in the PEP 1 treated group at 5 ⁇ M compared to the control group.
- HSP70 decreased by about 50% compared to the control group.
- treatment with scrambled peptides similar to PEP 1 but with different sequences did not significantly affect the levels of HSP70 and HSP90. (See Figures 4 and 5)
- HSP90 and HSP70 Reduction of HSP90 and HSP70 by PEP 1 can be more reliably confirmed by Flow Cytometric Analysis.
- the effect of PEP 1 treatment on HSP on the cell surface was less than that on cytoplasmic HSP, but it could reduce intracellular and cytoplasmic HSP90 and HSP70. Shown (see FIG. 9).
- Treatment with PEP 1 and proteasome inhibitor MG132 eliminated the effects of PEP 1, suggesting that PEP 1 may induce proteasome-dependent degradation of HSP90 and HSP70 (see FIG. 9). ).
- Tie2 plays a key role in the initiation of angiogenesis [Du R et al, Cancer cell, 13: 206-20, 2008].
- the effect of PEP 1 on recruiting TEM (Tie2 expressing monocytes) to tumors based on the finding that PEP 1 can destabilize HSP and inhibit HIF-1 ⁇ and VEGF expression in tumor cells.
- As a result of immunohistochemical staining it was confirmed that the number of Tie2 + CD11b + mononuclear leukocytes of tumors collected from PEP 1 treated mice was significantly lower than that of control mice (see FIGS. 12 and 13). . This indicates that inhibition of HIF-1 ⁇ and VEGF expression by PEP 1 significantly influences the induction of TEM, which is important for angiogenesis.
- HSP70 and HSP90 proteins in PEP 1 treated tumor samples were also confirmed by immunoblotting experiments with tumor lysates. Reductions in HSP70 and HSP90 were observed in all three PEP 1 treated tumor samples (see FIG. 16). In particular, HSP90 was rarely found in samples treated with PEP 1. GRP78, another family member of HSP, was also reduced in PEP 1 treated samples. Collectively, these results indicate that PEP 1 is capable of reducing HSP in vivo and inhibiting tumor growth.
- HSP70 and HSP90 can be secreted from tumor cells, and recent studies have shown some roles in tumorigenesis and antitumor responses.
- PEP 1 in HSP90 and HSP70 secretion the concentrations of HSP70 and HSP90 were measured from the blood of tumor-bearing mice. Although there was no change in the level of HSP90 secreted between the PEP 1 treated group and the control group, the HSP70 level of the PEP 1 treated rats was lower than that of the control group (see FIG. 17).
- HSP70 levels correlate with tumor amount and tumor weight (see FIG. 18).
- the mouse model was used to investigate the tumor suppression effect of PEP 1 in vivo.
- MC38 murine cancer cells were treated with PEP 1 and subcutaneous in vivo tumor growth was analyzed. A significant difference in the amount of tumor was observed between the group treated with PEP 1 and the control group (see FIG. 19). At 18 days post-injection, it was observed that the mean tumor amount of the control group was about three times that of the PEP 1 treated group. Consistently, the weight of the tumor in the control group is significantly greater than the weight of the tumor in the PEP 1 treated group, indicating that PEP 1 has the ability to inhibit tumor growth in vivo (see FIGS. 20, 21).
- This embodiment is a human umbilical vein endothelial cell (Human umbilical vein
- endothelial cells were cultured in EGM-2 medium, and only vascular endothelial cells between 2-5 passages were used for the experiment.
- VEGF-A vascular endothelial growth factor-A
- Endothelial cells were plated at 1x10 5 cells / well on 6-well plates (BD Biosciences, Bedford, Mass., USA). Synchronize cells to G1 / G0 phase with basic EBM-2 media (Lonza) without serum and angiogenic inducers, then treat PEP 1 with concentrations (0.05, 0.5, 5 ⁇ M) and 24 with EGM-2 media. By time stimulation, the effect of inhibiting cell proliferation was observed.
- PEP 1 concentration-dependently inhibited the proliferation of vascular endothelial cells stimulated with EGM-2 medium containing various angiogenic inducers (FIG. 1A), and it was confirmed that there was no effect on cell viability (FIG. 1B). . This suggests that PEP 1 has an effect of inhibiting proliferation without cytotoxicity on cell proliferation of vascular endothelial cells.
- Coronary changes were determined using Olympus CKX41 inverted microscope (CAchN 10 / 0.25php objective, Olympus Optical Co., Tokyo, Japan) and ToupTek Toupview software (version x86, 3.5.563, Hangzhou ToupTek Photonics Co., Zhejiang, PR China). Observation was carried out (FIG. 2A).
- PEP 1 can inhibit angiogenesis by vascular endothelial cell migration and differentiation by concentration-dependently inhibiting vascular endothelial cell stimulation with EGM-2 medium containing various angiogenic inducers (FIG. 2B). To present.
- Endothelial cells were plated at 1x10 5 cells / well on 6-well plates (BD Biosciences, Bedford, Mass., USA). After synthesizing the cells to the G1 / G0 phase with basic EBM-2 medium (Lonza) without serum and angiogenic inducers, PEP 1 was treated with concentrations (0.05, 0.5, 5 ⁇ M) and VEGF-A (10 ng). / mL) was stimulated for 24 hours to observe the effect of inhibiting cell proliferation.
- concentrations 0.05, 0.5, 5 ⁇ M
- VEGF-A 10 ng
- Coronary changes were determined using Olympus CKX41 inverted microscope (CAchN 10 / 0.25php objective, Olympus Optical Co., Tokyo, Japan) and ToupTek Toupview software (version x86, 3.5.563, Hangzhou ToupTek Photonics Co., Zhejiang, PR China). Observed by (Fig. 4a).
- PEP 1 inhibits vascular endothelial tube formation by VEGF-A in a concentration dependent manner (FIG. 4B).
- PEP 1 was treated with concentrations (0.05, 0.5, 5 ⁇ M) and stimulated with VEGF-A (10 ng / mL) for 18 hours, then the insert was fixed with methanol and the cotton-tipped swab was used to infiltrate the top of the insert. Uninoculated cells were removed. Infiltrating cells were directly counted under a microscope by staining with Giemsa stain solution (Sigma-Aldrich Co., St. Louis, MO, USA) and observing six different spots under a microscope (x200) (FIG. 6A).
- Giemsa stain solution Sigma-Aldrich Co., St. Louis, MO, USA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Abstract
Description
원래 아미노산 | 예시적인 잔기 치환 | 바람직한 잔기 치환 |
Ala (A) | val; leu; ile | Val |
Arg (R) | lys; gln; asn | Lys |
Asn (N) | gln; his; asp, lys; arg | Gln |
Asp (D) | glu; asn | Glu |
Cys (C) | ser; ala | Ser |
Gln (Q) | asn; glu | Asn |
Glu (E) | asp; gln | Asp |
Gly (G) | Ala | Ala |
His (H) | asn; gln; lys; arg | Arg |
Ile (I) | leu; val; met; ala; phe; norleucine | Leu |
Leu (L) | norleucine; ile ; val; met; ala; phe | Ile |
Lys (K) | arg; gln; asn | Arg |
Met (M) | leu; phe; ile | Leu |
Phe (F) | leu; val; ile; ala; tyr | Tyr |
Pro (P) | Ala | Ala |
Ser (S) | thr | Thr |
Thr (T) | Ser | Ser |
Trp (W) | tyr; phe | Tyr |
Tyr (Y) | trp; phe ; thr; ser | Phe |
Val (V) | ile; leu; met; phe; ala; norleucine | Leu |
Claims (15)
- 서열번호 1의 아미노산 서열을 포함하는 펩티드, 상기 아미노산 서열과 80% 이상의 서열 상동성을 갖는 펩티드 또는 그 단편인 펩티드를 포함하는 혈관 신생 억제용 조성물.
- 제 1항에 있어서, 상기 단편은 3개 이상의 아미노산으로 구성된 단편인 혈관 신생 억제용 조성물.
- 제1항에 있어서, 상기 조성물은 종양의 성장 및 전이, 당뇨병성 망막증, 미숙아 망막증, 각막 이식 거부, 신생혈관 녹내장, 홍색증, 증식성 망막증, 건선, 황반 변성(macular degeneration), 혈우병성 관절, 아테롬성 동맥경화 플라크 내에서의 모세혈관 증식, 켈로이드, 상처 과립화, 혈관 접착, 류마티스 관절염, 만성 염증 (chronic inflammation), 골관절염, 자가면역 질환, 크론씨병, 재발협착증, 아테롬성 동맥경화, 장관 접착, 캣 스크래치 질환, 궤양, 간경병증, 사구체신염, 당뇨병성 신장병증, 악성 신경화증, 혈전성 미소혈관증, 기관 이식 거부, 신사구체병증, 당뇨병, 염증 또는 신경퇴행성 질환의 비조절성 혈관신생-관련 질병 또는 질환의 예방 또는 치료에 이용되는 혈관신생 억제용 조성물.
- 제1항에 있어서, 상기 조성물은 종양의 성장 및 전이의 예방 또는 치료에 이용되는 혈관신생 억제용 조성물.
- 제1항에 있어서, 상기 조성물은 과도한 혈관 신생으로 인한 안과 질환의 예방 또는 치료에 이용되는 혈관신생 억제용 조성물.
- 제5항에 있어서, 상기 안과 질환은 당뇨병성 망막증, 미숙아 망막증, 각막 이식 거부, 신생혈관 녹내장, 홍색증, 증식성 망막증, 건선 또는 황반 변성(macular degeneration)인 혈관신생 억제용 조성물.
- 제 1 항에 있어서, 상기 조성물은 혈관내피세포의 증식, VEGF(Vascular endothelial growth factor)-유도 관 형성 및 혈관내피세포의 침투를 억제하는 것을 특징으로 하는 혈관신생 억제용 조성물.
- 제1항에 있어서, 상기 조성물은 약학 조성물인 혈관신생 억제용 조성물.
- 제1항에 있어서, 상기 조성물은 식품 조성물인 혈관신생 억제용 조성물.
- 제1항 내지 제9항 중 어느 한 항에 따른 혈관신생 억제용 조성물을 대상에게 투여하는 단계를 포함하는 혈관신생 관련 질환의 예방 및 치료방법.
- 제1항에 있어서, 상기 조성물은 혈관내피세포의 증식 또는 관형성을 억제하는 것을 특징으로 하는 혈관신생 억제용 조성물.
- 제1항에 있어서, 상기 조성물은 VEGF-A(Vascular endothelial growth factor-A)에 의한 혈관내피세포의 증식, 관형성 또는 혈관 내피세포에 대한 침윤을 억제하는 것을 특징으로 하는 혈관신생 억제용 조성물.
- 제1항에 있어서, 상기 조성물은 혈관신생과 관련된 질환의 예방 및 치료용 조성물.
- 제13항에 있어서, 상기 혈관신생과 관련된 질환은 종양의 성장 및 전이, 당뇨병성 망막증, 미숙아 망막증, 각막 이식 거부, 신생혈관 녹내장, 홍색증, 증식성 망막증, 건선, 황반 변성 (macular degeneration), 혈우병성 관절, 아테롬성 동맥경화 플라크 내에서의 모세혈관 증식, 켈로이드, 상처 과립화, 혈관 접착, 류마티스 관절염, 만성 염증 (chronic inflammation), 골관절염, 자가면역 질환, 크론씨병, 재발협착증, 아테롬성 동맥경화, 장관 접착, 캣 스크래치 질환, 궤양, 간경병증, 사구체신염, 당뇨병성 신장병증, 악성 신경화증, 혈전성 미소혈관증, 기관 이식 거부, 신사구체병증, 당뇨병, 염증 또는 신경퇴행성 질환의 비조절성인 혈관신생 억제용 조성물.
- 제1항 내지 제2항 및 제11항 내지 제14항 중 어느 한 항에 따른 혈관신생 억제용 조성물을 필요로 하는 대상에게 투여하는 것을 특징으로 하는 혈관신생 관련 질환을 치료 및 예방하는 방법.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016533182A JP6553605B2 (ja) | 2013-11-22 | 2014-11-21 | 血管新生抑制活性を有するペプチド、及びそれを含む組成物 |
KR1020227003326A KR102494803B1 (ko) | 2013-11-22 | 2014-11-21 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
ES14864515T ES2818921T3 (es) | 2013-11-22 | 2014-11-21 | Péptido que tiene actividad inhibidora de la angiogénesis y composición que contiene el mismo |
US15/038,269 US10034922B2 (en) | 2013-11-22 | 2014-11-21 | Peptide having angiogenesis inhibitory activity and composition containing same |
EP14864515.3A EP3072519B1 (en) | 2013-11-22 | 2014-11-21 | Peptide having angiogenesis inhibitory activity and composition containing same |
CN201480070167.3A CN105848667B (zh) | 2013-11-22 | 2014-11-21 | 具有血管生成抑制活性的肽和包含所述肽的组合物 |
KR1020237003083A KR20230020009A (ko) | 2013-11-22 | 2014-11-21 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
KR1020167015069A KR102359396B1 (ko) | 2013-11-22 | 2014-11-21 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0142897 | 2013-11-22 | ||
KR20130142897 | 2013-11-22 | ||
KR10-2014-0020605 | 2014-02-21 | ||
KR20140020605 | 2014-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015076621A1 true WO2015076621A1 (ko) | 2015-05-28 |
Family
ID=53179816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/011280 WO2015076621A1 (ko) | 2013-11-22 | 2014-11-21 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10034922B2 (ko) |
EP (1) | EP3072519B1 (ko) |
JP (1) | JP6553605B2 (ko) |
KR (3) | KR102494803B1 (ko) |
CN (1) | CN105848667B (ko) |
ES (1) | ES2818921T3 (ko) |
WO (1) | WO2015076621A1 (ko) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9540419B2 (en) | 2012-05-11 | 2017-01-10 | Gemvax & Kael Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
US9730984B2 (en) | 2012-05-11 | 2017-08-15 | Gemvax & Kael Co., Ltd. | Composition for preventing or treating rheumatoid arthritis |
US9907838B2 (en) | 2013-04-19 | 2018-03-06 | Gemvax & Kael Co., Ltd. | Composition and methods for treating ischemic damage |
US9937240B2 (en) | 2014-04-11 | 2018-04-10 | Gemvax & Kael Co., Ltd. | Peptide having fibrosis inhibitory activity and composition containing same |
US10383926B2 (en) | 2013-06-07 | 2019-08-20 | Gemvax & Kael Co., Ltd. | Biological markers useful in cancer immunotherapy |
US10463708B2 (en) | 2014-12-23 | 2019-11-05 | Gemvax & Kael Co., Ltd. | Peptide for treating ocular diseases and composition for treating ocular diseases comprising same |
US10561703B2 (en) | 2013-06-21 | 2020-02-18 | Gemvax & Kael Co., Ltd. | Method of modulating sex hormone levels using a sex hormone secretion modulator |
US10662223B2 (en) | 2014-04-30 | 2020-05-26 | Gemvax & Kael Co., Ltd. | Composition for organ, tissue, or cell transplantation, kit, and transplantation method |
US10835582B2 (en) | 2015-02-27 | 2020-11-17 | Gemvax & Kael Co. Ltd. | Peptide for preventing hearing loss, and composition comprising same |
US10898540B2 (en) | 2016-04-07 | 2021-01-26 | Gem Vax & KAEL Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
US10967000B2 (en) | 2012-07-11 | 2021-04-06 | Gemvax & Kael Co., Ltd. | Cell-penetrating peptide, conjugate comprising same and composition comprising same |
US11015179B2 (en) | 2015-07-02 | 2021-05-25 | Gemvax & Kael Co., Ltd. | Peptide having anti-viral effect and composition containing same |
US11058744B2 (en) | 2013-12-17 | 2021-07-13 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10632349B2 (en) | 2017-11-03 | 2020-04-28 | Parsons Xtreme Golf, LLC | Golf club heads and methods to manufacture golf club heads |
CN110225922B (zh) * | 2017-01-13 | 2023-09-12 | 血管免疫治疗公司 | 用于促进血管生成的剂及其方法和用途 |
CN108421050A (zh) * | 2017-02-15 | 2018-08-21 | 闵晓洁 | 小分子rna干扰端粒酶逆转录酶质粒抑制视网膜、脉络膜新生血管新制剂 |
KR101998155B1 (ko) | 2017-09-22 | 2019-07-10 | (주)케어젠 | 혈관신생 억제용 펩타이드 및 이의 용도 |
KR102467670B1 (ko) * | 2022-05-16 | 2022-11-17 | 줄리아 연구소 주식회사 | Shc1 단백질 또는 항-shc1 항체를 포함하는 혈관신생성 질환의 예방, 치료 또는 개선용 약학적 조성물 및 건강기능식품 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030027769A1 (en) * | 2001-02-16 | 2003-02-06 | Scialdone Mark A. | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
US20030143228A1 (en) * | 2001-10-29 | 2003-07-31 | Baylor College Of Medicine | Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen |
US20070190561A1 (en) * | 1996-10-01 | 2007-08-16 | Geron Corporation | Segments of the Human Gene for Telomerase Reverse Transcriptase |
US20110135692A1 (en) * | 2008-06-16 | 2011-06-09 | Genovax S.R.L. | Anti-tumor immunotherapy |
US20130129760A1 (en) * | 2010-02-16 | 2013-05-23 | Gustav Gaudernack | Polypeptides |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR930001915B1 (ko) | 1990-06-27 | 1993-03-20 | 포항종합제철 주식회사 | 저온 소결 압전요업재료 제조방법 |
EP0930876B2 (en) | 1996-07-22 | 2010-07-07 | Renovo Limited | Use of compounds that promote oestrogenic activity for acclerating the healing of skin wounds |
SK155799A3 (en) | 1997-05-15 | 2000-06-12 | Chugai Pharmaceutical Co Ltd | Cachexia remedy |
JP2002514928A (ja) | 1997-07-01 | 2002-05-21 | キャンビア バイオシステムス リミティド ライアビリティー カンパニー | 脊椎動物テロメラーゼ遺伝子およびタンパク質ならびにその使用 |
US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
IL132406A0 (en) | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
EP1360205A1 (en) * | 2001-02-16 | 2003-11-12 | E.I. Dupont De Nemours And Company | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
CN1237969C (zh) | 2001-04-10 | 2006-01-25 | 日本新药株式会社 | 慢性关节风湿病的治疗剂 |
KR100877033B1 (ko) | 2001-05-16 | 2009-01-07 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 패혈증의 치료 또는 예방을 위한 il-18 저해물질의 용도 |
US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
PL372928A1 (en) | 2002-04-10 | 2005-08-08 | Applied Research Systems Ars Holding N.V. | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
KR20050020987A (ko) | 2002-06-12 | 2005-03-04 | 바이오겐 아이덱 엠에이 인코포레이티드 | 아데노신 수용체 길항제를 사용하여 허혈 재관류 손상을치료하는 방법 |
CN1812805A (zh) | 2003-06-25 | 2006-08-02 | 坎巴斯有限公司 | 具有免疫调节活性、抗炎活性和抗病毒活性的肽和肽模仿物 |
KR20050040517A (ko) | 2003-10-29 | 2005-05-03 | 주식회사 오리엔트 | 허혈성 질환에 대한 저항성을 나타내는 형질전환 생쥐 |
DK1530965T3 (da) | 2003-11-11 | 2006-07-17 | Mattern Udo | Kontrolleret frigivelsesleveringssystem til nasal applikation |
GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
CA2646131C (en) | 2005-03-21 | 2018-09-04 | Vicus Therapeutics Spe 1, Llc | Compositions and methods for ameliorating cachexia |
AR057941A1 (es) | 2005-11-25 | 2007-12-26 | Univ Keio | Agentes terapeuticos para el cancer de prostata |
JP2009519033A (ja) | 2005-12-16 | 2009-05-14 | ディアト | 核酸を細胞に送達するための細胞貫通ペプチド結合体 |
WO2007097561A1 (en) | 2006-02-20 | 2007-08-30 | Ewha University - Industry Collaboration Foundation | Peptide having cell membrane penetrating activity |
JP2009544688A (ja) | 2006-07-24 | 2009-12-17 | フォーヒューマンテック カンパニー リミテッド | 虚血性疾患の緩和及び治療のための医薬組成物並びにそれを伝達するための方法 |
WO2008043760A1 (en) * | 2006-10-12 | 2008-04-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof |
AU2008211854C1 (en) | 2007-01-29 | 2014-01-23 | Procell Therapeutics Inc. | Novel macromolecule transduction domains and methods for identification and uses thereof |
SG182976A1 (en) | 2007-06-29 | 2012-08-30 | Ahngook Pharmaceutical Co Ltd | Predictive markers for ovarian cancer |
US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
CL2008002782A1 (es) * | 2007-09-21 | 2009-07-31 | Genentech Inc | Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular. |
US20090136917A1 (en) | 2007-10-25 | 2009-05-28 | Szalay Aladar A | Systems and methods for viral therapy |
GB2455539B (en) | 2007-12-12 | 2012-01-18 | Cambridge Entpr Ltd | Anti-inflammatory compositions and combinations |
ES2334315B1 (es) | 2008-07-29 | 2011-02-28 | Universitat Pompeu Fabra | Peptidos con capacidad de penetracion celular y sus usos. |
US20110183925A1 (en) | 2008-09-22 | 2011-07-28 | Nisshin Pharma Inc. | Anti-inflammatory peptide |
KR101169030B1 (ko) | 2009-01-21 | 2012-07-26 | 애니젠 주식회사 | 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 |
EP2251028A1 (en) | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor |
US7928067B2 (en) | 2009-05-14 | 2011-04-19 | Ischemix Llc | Compositions and methods for treating ischemia and ischemia-reperfusion injury |
ES2546304T3 (es) | 2009-05-20 | 2015-09-22 | Toray Industries, Inc. | Péptidos permeables para la membrana celular |
KR20110057049A (ko) | 2009-11-23 | 2011-05-31 | 박의신 | 기능성 전립선염 치료제 |
KR20110062943A (ko) | 2009-12-04 | 2011-06-10 | 주식회사종근당 | 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제 |
ES2664866T3 (es) | 2010-01-11 | 2018-04-23 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg |
KR101335203B1 (ko) * | 2010-03-26 | 2013-11-29 | 숙명여자대학교산학협력단 | 혈관신생촉진용 펩타이드 및 이의 용도 |
FR2960542B1 (fr) | 2010-05-27 | 2012-08-17 | Esther Suzy Arlette Fellous | Peptide en tant que medicament, en particulier pour le traitement du cancer |
KR101263212B1 (ko) | 2010-05-28 | 2013-05-10 | 성신여자대학교 산학협력단 | 신규한 세포막 투과성 펩타이드 및 그의 용도 |
WO2011150493A1 (en) | 2010-05-30 | 2011-12-08 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for antimicrobials |
WO2011155803A2 (ko) | 2010-06-11 | 2011-12-15 | 아주대학교산학협력단 | 청각보호 작용을 하는 신규 화합물 |
KR101348284B1 (ko) | 2010-09-09 | 2014-01-03 | 주식회사 나이벡 | 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
KR20120121196A (ko) | 2011-04-26 | 2012-11-05 | 주식회사 글루칸 | 관절염 치료제 |
KR101284772B1 (ko) | 2011-05-24 | 2013-07-17 | 정종문 | 항염증, 진통효과를 가지는 기능성 식품 조성물 |
KR20120133661A (ko) | 2011-05-31 | 2012-12-11 | 주식회사 바이오포트코리아 | 아스타잔틴을 포함하는 항염증제 |
KR101288053B1 (ko) | 2011-07-04 | 2013-07-23 | 동국대학교 산학협력단 | 필발 추출물을 유효성분으로 포함하는 내이손상 예방 및 치료용 조성물 |
KR101361445B1 (ko) | 2011-12-26 | 2014-02-12 | 성균관대학교산학협력단 | 펩타이드, 5-플루오로우라실, 및 성숙수지상세포를 포함하는 암 치료용 약학적 조성물 |
DE13746292T1 (de) | 2012-02-10 | 2014-10-30 | Hakushinkouseikai Foundation | Proliferationsmittel für monozyten, kulturmedium zur proliferation von monozyten, verfahren zur herstellung von monozyten, verfahren zur herstellung dendritischer zellen und verfahren zur herstellung eines impfstoffs mit dendritischen zellen |
KR102041381B1 (ko) | 2012-03-12 | 2019-11-27 | 젬백스 에이에스 | 능동적인 면역치료법을 이용한 비-소세포성 폐암의 치료 |
US9527888B2 (en) | 2012-05-11 | 2016-12-27 | Gemvax & Kael Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
KR101873773B1 (ko) | 2012-05-11 | 2018-08-02 | 주식회사 젬백스앤카엘 | 류마티즘 관절염 예방 또는 치료 조성물 |
US10967000B2 (en) | 2012-07-11 | 2021-04-06 | Gemvax & Kael Co., Ltd. | Cell-penetrating peptide, conjugate comprising same and composition comprising same |
US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
KR102038487B1 (ko) | 2012-09-19 | 2019-10-30 | 주식회사 젬백스앤카엘 | 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물 |
US9572900B2 (en) | 2012-09-19 | 2017-02-21 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
TWI598441B (zh) | 2012-09-19 | 2017-09-11 | 傑姆維克斯&凱爾有限公司 | 穿膜胜肽以及包含該胜肽之共軛物及組成物(四) |
ES2802253T3 (es) | 2012-09-19 | 2021-01-18 | Gemvax & Kael Co Ltd | Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado |
US9907838B2 (en) | 2013-04-19 | 2018-03-06 | Gemvax & Kael Co., Ltd. | Composition and methods for treating ischemic damage |
RU2677277C2 (ru) | 2013-06-07 | 2019-01-16 | Джемвакс Энд Каэл Ко., Лтд. | Биологические маркеры, которые могут быть использованы в иммунотерапии рака |
EP3011967B1 (en) | 2013-06-21 | 2020-06-17 | Gemvax & Kael Co., Ltd. | Hormone secretion regulator, composition containing same, and method for controlling hormone secretion using same |
KR101691479B1 (ko) | 2013-10-23 | 2017-01-02 | 주식회사 젬백스앤카엘 | 전립선 비대증 치료 및 예방용 조성물 |
US11058744B2 (en) | 2013-12-17 | 2021-07-13 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
JP6420459B2 (ja) | 2014-04-11 | 2018-11-07 | ジェムバックス アンド カエル カンパニー,リミティド | 線維症抑制活性を有するペプチド及びこれを含む組成物 |
CN106659149B (zh) | 2014-04-30 | 2020-05-19 | 珍白斯凯尔有限公司 | 用于器官、组织或细胞移植的组合物、试剂盒和移植方法 |
WO2015182798A1 (ko) * | 2014-05-28 | 2015-12-03 | 주식회사 카엘젬백스 | 골수-유래 억제세포(myeloid-derived suppressor cells, mdscs) 저해용 조성물 |
KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
CN107405380B (zh) | 2015-02-27 | 2021-04-20 | 珍白斯凯尔有限公司 | 用于预防听觉损伤的肽及其包含该肽的组合物 |
KR20170054310A (ko) | 2015-11-09 | 2017-05-17 | 주식회사 젬백스앤카엘 | 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법 |
-
2014
- 2014-11-21 KR KR1020227003326A patent/KR102494803B1/ko active IP Right Grant
- 2014-11-21 JP JP2016533182A patent/JP6553605B2/ja active Active
- 2014-11-21 KR KR1020237003083A patent/KR20230020009A/ko not_active Application Discontinuation
- 2014-11-21 WO PCT/KR2014/011280 patent/WO2015076621A1/ko active Application Filing
- 2014-11-21 US US15/038,269 patent/US10034922B2/en active Active
- 2014-11-21 CN CN201480070167.3A patent/CN105848667B/zh active Active
- 2014-11-21 EP EP14864515.3A patent/EP3072519B1/en active Active
- 2014-11-21 ES ES14864515T patent/ES2818921T3/es active Active
- 2014-11-21 KR KR1020167015069A patent/KR102359396B1/ko active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070190561A1 (en) * | 1996-10-01 | 2007-08-16 | Geron Corporation | Segments of the Human Gene for Telomerase Reverse Transcriptase |
US20030027769A1 (en) * | 2001-02-16 | 2003-02-06 | Scialdone Mark A. | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
US20030143228A1 (en) * | 2001-10-29 | 2003-07-31 | Baylor College Of Medicine | Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen |
US20110135692A1 (en) * | 2008-06-16 | 2011-06-09 | Genovax S.R.L. | Anti-tumor immunotherapy |
US20130129760A1 (en) * | 2010-02-16 | 2013-05-23 | Gustav Gaudernack | Polypeptides |
Non-Patent Citations (29)
Title |
---|
BOHONOWYCH JE ET AL., BMC CANCER, vol. 11, 2011, pages 520 |
BRUNS AF ET AL., PLOS ONE, vol. 7, 2012, pages E48539 |
CALDERWOOD SK ET AL., TRENDS IN BIOCHEMICAL SCIENCES, vol. 31, 2006, pages 164 - 72 |
CALDERWOOD SK, TRENDS IN BIOCHEMICAL SCIENCES, vol. 31, 2006, pages 164 - 72 |
DEMPSEY NC ET AL., JOURNAL OF LEUKOCYTE BIOLOGY, vol. 87, 2010, pages 467 - 76 |
DU R ET AL., CANCER CELL, vol. 13, 2008, pages 206 - 20 |
EUSTACE BK ET AL., CELL CYCLE, vol. 3, 2004, pages 1098 - 100 |
EUSTACE BK ET AL., NATURE CELL BIOLOGY, vol. 6, 2004, pages 507 - 14 |
EVANS CG ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, 2010, pages 4585 - 602 |
FERRARINI M ET AL., JOURNAL INTERNATIONAL DU CANCER, vol. 51, 1992, pages 613 - 9 |
GANJI PN ET AL., ANGIOGENESIS, vol. 16, 2013, pages 903 - 17 |
GARCIA-CARBONERO R ET AL., THE LANCET ONCOLOGY, vol. 14, 2013, pages E358 - 69 |
GONG W ET AL., ONCOLOGY REPORTS, 2013 |
JAATTELA M, INTERNATIONAL JOURNAL OF CANCER JOURNAL INTERNATIONAL DU CANCER, vol. 60, 1995, pages 689 - 93 |
KIM ET AL.: "Tumor-suppressive effect of a telomerase-derived peptide by inhibiting hypoxia-induced HIF-la-VEGF signaling axis", BIOMATERIALS, vol. 35, 8 January 2014 (2014-01-08), pages 2924 - 2933, XP028829049 * |
KOCSIS J ET AL., CELL STRESS & CHAPERONES, vol. 15, 2010, pages 143 - 51 |
MORANO KA, ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 1113, 2007, pages 1 - 14 |
MURPHY ME, CARCINOGENESIS, vol. 34, 2013, pages 1181 - 8 |
PFOSSER A ET AL., CARDIOVASCULAR RESEARCH, vol. 65, 2005, pages 728 - 36 |
POWERS MV ET AL., CELL CYCLE, vol. 9, 2010, pages 1542 - 50 |
See also references of EP3072519A4 |
SEO JS ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 218, 1996, pages 582 - 7 |
SUN J ET AL., ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY, vol. 24, 2004, pages 2238 - 44 |
SUN J ET AL., ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 24, 2004, pages 2238 - 44 |
UEHARA Y, CURRENT CANCER DRUG TARGETS, vol. 3, 2003, pages 325 - 30 |
VANBUSKIRK A ET AL., THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 170, 1989, pages 1799 - 809 |
VOLLOCH VZ ET AL., ONCOGENE, vol. 18, 1999, pages 3648 - 51 |
YEH CH ET AL., LEUKEMIA RESEARCH, vol. 34, 2010, pages 605 - 9 |
ZHOU J ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, 2004, pages 13506 - 13 |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10039811B2 (en) | 2012-05-11 | 2018-08-07 | Gemvax & Kael Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
US9540419B2 (en) | 2012-05-11 | 2017-01-10 | Gemvax & Kael Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
US9844584B2 (en) | 2012-05-11 | 2017-12-19 | Gemvax & Kael Co., Ltd. | Composition for preventing or treating sepsis |
US9907837B2 (en) | 2012-05-11 | 2018-03-06 | Gemvax & Kael Co., Ltd. | Composition for preventing or treating cachexia |
US10960056B2 (en) | 2012-05-11 | 2021-03-30 | Gemvax & Kael Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
US11369665B2 (en) | 2012-05-11 | 2022-06-28 | Gemvax & Kael Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
US9730984B2 (en) | 2012-05-11 | 2017-08-15 | Gemvax & Kael Co., Ltd. | Composition for preventing or treating rheumatoid arthritis |
US11857607B2 (en) | 2012-05-11 | 2024-01-02 | Gemvax & Kael Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
US10967000B2 (en) | 2012-07-11 | 2021-04-06 | Gemvax & Kael Co., Ltd. | Cell-penetrating peptide, conjugate comprising same and composition comprising same |
US9907838B2 (en) | 2013-04-19 | 2018-03-06 | Gemvax & Kael Co., Ltd. | Composition and methods for treating ischemic damage |
US10383926B2 (en) | 2013-06-07 | 2019-08-20 | Gemvax & Kael Co., Ltd. | Biological markers useful in cancer immunotherapy |
US10561703B2 (en) | 2013-06-21 | 2020-02-18 | Gemvax & Kael Co., Ltd. | Method of modulating sex hormone levels using a sex hormone secretion modulator |
US11058744B2 (en) | 2013-12-17 | 2021-07-13 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
US9937240B2 (en) | 2014-04-11 | 2018-04-10 | Gemvax & Kael Co., Ltd. | Peptide having fibrosis inhibitory activity and composition containing same |
US10662223B2 (en) | 2014-04-30 | 2020-05-26 | Gemvax & Kael Co., Ltd. | Composition for organ, tissue, or cell transplantation, kit, and transplantation method |
US11077163B2 (en) | 2014-12-23 | 2021-08-03 | Gemvax & Kael Co., Ltd. | Peptide for treating ocular diseases and composition for treating ocular diseases comprising same |
US10463708B2 (en) | 2014-12-23 | 2019-11-05 | Gemvax & Kael Co., Ltd. | Peptide for treating ocular diseases and composition for treating ocular diseases comprising same |
US10835582B2 (en) | 2015-02-27 | 2020-11-17 | Gemvax & Kael Co. Ltd. | Peptide for preventing hearing loss, and composition comprising same |
US11015179B2 (en) | 2015-07-02 | 2021-05-25 | Gemvax & Kael Co., Ltd. | Peptide having anti-viral effect and composition containing same |
US10898540B2 (en) | 2016-04-07 | 2021-01-26 | Gem Vax & KAEL Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
Also Published As
Publication number | Publication date |
---|---|
EP3072519A1 (en) | 2016-09-28 |
JP6553605B2 (ja) | 2019-07-31 |
KR20230020009A (ko) | 2023-02-09 |
KR102359396B1 (ko) | 2022-02-08 |
KR20160079881A (ko) | 2016-07-06 |
CN105848667A (zh) | 2016-08-10 |
US10034922B2 (en) | 2018-07-31 |
ES2818921T3 (es) | 2021-04-14 |
KR20220020411A (ko) | 2022-02-18 |
US20160296604A1 (en) | 2016-10-13 |
EP3072519A4 (en) | 2017-04-19 |
KR102494803B1 (ko) | 2023-02-06 |
JP2016539121A (ja) | 2016-12-15 |
CN105848667B (zh) | 2020-05-19 |
EP3072519B1 (en) | 2020-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015076621A1 (ko) | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 | |
WO2015156649A1 (ko) | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 | |
WO2013169077A1 (ko) | 악액질 예방 또는 치료용 조성물 | |
AU2014255755B2 (en) | Medical use of syndecan-2 | |
WO2014046490A1 (ko) | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 | |
WO2017078440A1 (ko) | 신경세포 손실 예방 및 재생 효능을 가지는 펩티드 및 이를 포함하는 조성물 | |
WO2014046478A1 (ko) | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 | |
WO2015093854A1 (ko) | 전립선 암 치료용 조성물 | |
WO2015060673A1 (ko) | 전립선 비대증 치료 및 예방용 조성물 | |
WO2015167067A1 (ko) | 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법 | |
WO2019212324A1 (ko) | 멜리틴-기반 세포사멸 유발 펩타이드로 m2 유사 종앙관련 대식세포의 표적화 | |
WO2017022962A1 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
WO2020153605A1 (ko) | 메소텔린 특이적인 키메라 항원 수용체 및 이를 발현하는 t 세포 | |
WO2015005723A1 (ko) | 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 | |
WO2011052883A2 (ko) | Socs2 유전자의 발현을 조절하여 자연 살해 세포를 활성화시키는 방법 | |
WO2019194586A1 (en) | Novel target for anti-cancer and immune-enhancing | |
WO2018186706A1 (ko) | Nk 세포 활성화 융합 단백질, nk 세포 및 이들을 포함하는 약제학적 조성물 | |
WO2021194186A1 (ko) | Vgll1 펩타이드를 포함하는 암 치료용 조성물 | |
WO2015182798A1 (ko) | 골수-유래 억제세포(myeloid-derived suppressor cells, mdscs) 저해용 조성물 | |
WO2021107635A1 (ko) | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 nk 세포를 포함하는 항암 치료용 조성물 | |
WO2014010985A1 (ko) | 세포내 단백질의 고효율 도입 및 유지용 펩타이드 | |
WO2023153773A1 (ko) | C-met의 에피토프를 포함하는 암 백신 및 이의 용도 | |
WO2023195802A1 (ko) | 신규 펩타이드 기반 면역항암제 | |
WO2023153763A1 (ko) | C-met의 에피토프 및 hif1alpha의 에피토프를 포함하는 암 백신 및 이의 용도 | |
WO2017164486A1 (ko) | Tesk1 억제제를 포함하는 항암제 내성 억제용 조성물 및 tesk1 억제제의 스크리닝 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14864515 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016533182 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15038269 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014864515 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014864515 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20167015069 Country of ref document: KR Kind code of ref document: A |